Aclaris Therapeutics ACRS Contingent Consideration Liability (Non-Current)
Contingent Consideration Liability (Non-Current) at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's contingent consideration liability (non-current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's contingent consideration liability (non-current)?
- Aclaris Therapeutics (ACRS) reported contingent consideration liability (non-current) of $11M in Q1 2026.
- How has Aclaris Therapeutics's contingent consideration liability (non-current) changed year-over-year?
- Aclaris Therapeutics's contingent consideration liability (non-current) increased by 22.2% year-over-year, from $9M to $11M.
- What is the long-term trend for Aclaris Therapeutics's contingent consideration liability (non-current)?
- Over 5 years (2020 to 2025), Aclaris Therapeutics's contingent consideration liability (non-current) has grown at a 22.1% compound annual growth rate (CAGR), from $4.06M to $11M.
- What does contingent consideration liability (non-current) mean?
- This represents the long-term portion of obligations to pay additional consideration to sellers following a business acquisition, typically triggered by the achievement of specific clinical or commercial milestones. It reflects the company's future financial commitments tied to the success of acquired assets or research programs. Investors use this to evaluate potential future cash outflows and the risk profile associated with the company's inorganic growth strategy.